VIVOS THERAPEUTICS INC 2026 Q2
Earnings Overview & AI Insights

Earnings Performance

Summary of Financial Performance: Vivos Therapeutics reported Q2 2026 revenue of $5.2 million, up 35% year over year, driven mainly by a $1.9 million increase in service revenue, partially offset by lower product revenue as the company continues shifting away from VIPs toward sleep-center-led treatment. Six-month revenue rose 51% to $10.3 million. Gross profit improved to $3.0 million in Q2 and $6.0 million year to date, with gross margin expanding to 57% in Q2 and 58% year to date. However, operating losses remain significant, with a net loss of $5.5 million for the quarter and $13.3 million year to date. Cash on hand was only $1.8 million at quarter-end, and the company cited substantial doubt about its ability to continue as a going concern without additional financing.

Company Outlook & Strategy: Management reiterated a strategic pivot toward sleep centers, recurring services, physician referrals, and clinically appropriate pathways into Vivos treatment. Leadership expects this model to support positive cash flow near the end of 2026 or early 2027 and significant positive EBITDA in fiscal 2027. Key growth initiatives include remote patient monitoring for CPAP patients, a planned DME-based CPAP program, expanded insomnia/EEG testing and treatment, pediatric OSA programs, and new cardiology affiliations in Arizona and Florida. Management emphasized disciplined scaling, improved economics, and the long-term goal of building a stronger recurring-revenue platform.

Key Industry Trends: The call highlighted growing demand for sleep and airway medicine services, especially across obstructive sleep apnea, CPAP monitoring, insomnia testing, and pediatric sleep disorders. Management stressed broad payer participation in EEG testing reimbursements, particularly in Nevada, and noted significant unmet need in pediatric sleep care. The company also framed its model as addressing inefficiencies in traditional sleep medicine, where patients often fall out of the care pathway.

Operational Highlights: Vivos completed the first full year of SCN contribution and reported that integration is beginning to generate tangible operating synergies. The company expanded Henderson, Nevada capacity, more than doubling production potential there to over $10 million annually. Referral flow from SCN physicians to SAMC has accelerated, with 3x to 4x more patient referrals since quarter-end, expected to impact Q3 results. The pediatric program is now active with hundreds of children receiving treatment. EEG/insomnia services are scaling, and the company expects new cardiology partnerships to add meaningful capacity and revenue once finalized.

Challenges & Risks: The most pressing risks are liquidity, going concern uncertainty, and NASDAQ compliance. Vivos does not have enough cash to fund operations for the next 12 months and is pursuing financing and cost reductions to restore compliance with the minimum $2.5 million stockholders’ equity requirement. Execution risk remains high across new initiatives, including patient enrollment, reimbursement, payer contracting, staffing, facility readiness, and scaling the new programs. Higher costs tied to SCN integration, staffing, diagnostics, and interest expense also pressured results.

Key Analyst Questions & Responses: Analysts asked about the planned cardiology partnerships in Florida and Arizona; management said each would require roughly $800,000 to $1 million of capex and could begin generating revenue in Q1 to Q2 2027. On the insomnia/EEG program, management said reimbursement is encouraging, with EEG testing averaging about $800 per patient and broad payer participation, though treatment reimbursement is still early and not yet well established. Management also said third-quarter 2026 should begin to show more visible financial benefits from the new initiatives, with stronger growth expected into 2027.